- Home
- IMPP vs EDIT Comparison
IMPP vs EDIT Comparison
Compare IMPP & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- EDIT
- Stock Information
- Founded
- IMPP 1981
- EDIT 2013
- Country
- IMPP Greece
- EDIT United States
- Employees
- IMPP N/A
- EDIT N/A
- Industry
- IMPP Marine Transportation
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMPP Consumer Discretionary
- EDIT Health Care
- Exchange
- IMPP Nasdaq
- EDIT Nasdaq
- Market Cap
- IMPP 99.2M
- EDIT 108.1M
- IPO Year
- IMPP N/A
- EDIT 2016
- Fundamental
- Price
- IMPP $2.44
- EDIT $1.18
- Analyst Decision
- IMPP
- EDIT Buy
- Analyst Count
- IMPP 0
- EDIT 14
- Target Price
- IMPP N/A
- EDIT $8.08
- AVG Volume (30 Days)
- IMPP 127.4K
- EDIT 2.0M
- Earning Date
- IMPP 05-15-2025
- EDIT 03-05-2025
- Dividend Yield
- IMPP N/A
- EDIT N/A
- EPS Growth
- IMPP N/A
- EDIT N/A
- EPS
- IMPP 1.40
- EDIT N/A
- Revenue
- IMPP $147,479,980.00
- EDIT $32,314,000.00
- Revenue This Year
- IMPP $3.05
- EDIT N/A
- Revenue Next Year
- IMPP $47.92
- EDIT N/A
- P/E Ratio
- IMPP $1.75
- EDIT N/A
- Revenue Growth
- IMPP N/A
- EDIT N/A
- 52 Week Low
- IMPP $2.23
- EDIT $1.12
- 52 Week High
- IMPP $4.59
- EDIT $7.09
- Technical
- Relative Strength Index (RSI)
- IMPP 39.85
- EDIT 40.57
- Support Level
- IMPP $2.35
- EDIT $1.24
- Resistance Level
- IMPP $2.60
- EDIT $1.32
- Average True Range (ATR)
- IMPP 0.08
- EDIT 0.09
- MACD
- IMPP 0.01
- EDIT -0.03
- Stochastic Oscillator
- IMPP 36.00
- EDIT 15.79
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.